Q-omics provides the consensus-scored MTND6P18 profile across patient tissues and cancer cell-line models. MTND6P18 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MTND6P18 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, MTND6P18 RNA expression shows 6,171 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, HNSC, and STAD as cancer lineages where MTND6P18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND6P18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND6P18 survival associations across molecular data types. MTND6P18 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND6P18 RNA expression–survival associations across cancer types. High MTND6P18 expression shows unfavorable associations in ESCA, BRCA, KIRC, THCA and BLCA, but favorable associations in LAML. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ESCA as the clearest survival context for MTND6P18 RNA expression.
This table summarizes MTND6P18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTND6P18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND6P18 shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, BRCA and LIHC. The HNSC box plot shows higher MTND6P18 RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p = .011).
This table shows molecular features associated with MTND6P18 in patient tissues and cancer cell lines. In patient samples, MTND6P18 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
